Last reviewed · How we verify
Continuation Therapy for Acute Osteomyelitis — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Methocillin S | CLOXACILLIN | GSK | cloxacillin | 1974-01-01 | ||
| Bactocill In Plastic Container | OXACILLIN | Apothecon | Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 | 1971-01-01 | ||
| Pathocil | DICLOXACILLIN | Pfizer | Penicillin-class Antibacterial | Muscarinic acetylcholine receptor M1 | 1968-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Apothecon · 1 drug in Continuation Therapy for Acute Osteomyelitis
- GSK · 1 drug in Continuation Therapy for Acute Osteomyelitis
- Pfizer · 1 drug in Continuation Therapy for Acute Osteomyelitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Continuation Therapy for Acute Osteomyelitis:
- Continuation Therapy for Acute Osteomyelitis treatment updates — RSS
- Continuation Therapy for Acute Osteomyelitis treatment updates — Atom
- Continuation Therapy for Acute Osteomyelitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Continuation Therapy for Acute Osteomyelitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/continuation-therapy-for-acute-osteomyelitis. Accessed 2026-06-10.
Related
- Continuation Therapy for Acute Osteomyelitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing